Diphtheria
Diphtheria is an acute and contagious disease primarily affecting children, caused by the bacterium *Corynebacterium diphtheriae*, which produces a harmful toxin. The disease typically presents with symptoms including a sore throat, malaise, mild fever, and the formation of a thick pseudomembrane in the throat, which can lead to respiratory difficulties. In severe cases, the toxin can enter the bloodstream, causing damage to vital organs such as the heart and nervous system. Diphtheria is spread through respiratory droplets or contaminated surfaces and can also manifest as a skin infection characterized by slow-healing ulcers.
Prompt treatment is crucial and generally involves antibiotics like penicillin or erythromycin, along with antitoxin administration to neutralize the effects of the toxin. Vaccination with diphtheria toxoid has been effective in preventing the disease, with immunization programs recommended for children and periodic boosters for adults. Although diphtheria was once a significant health threat in many parts of the world, its incidence has dramatically decreased in developed countries due to successful vaccination efforts. However, it remains a public health concern in some developing regions, where outbreaks can still occur.
Diphtheria
ANATOMY OR SYSTEM AFFECTED: Heart, nervous system, throat
DEFINITION: An acute, contagious disease found primarily in children, associated with toxin production by the bacterium Corynebacterium diphtheriae.
CAUSES: Toxin production by bacteria
SYMPTOMS: Sore throat, malaise, mild fever, pseudomembrane formation in throat; when systemic, damage to heart, nervous system, or other organs
DURATION: Acute
TREATMENTS: Antibiotics (penicillin, erythromycin), antitoxin
Causes and Symptoms
The etiological agent of diphtheria, Corynebacterium diphtheriae, is found in some individuals as an inhabitant of the nasopharynx (nose and throat). Its symptoms are associated with the production of a toxin. Only those strains of the carrying a bacteriophage in a lysogenic state produce the toxin. Spread of diphtheria is generally person to person through respiratory secretions or through contaminated environmental surfaces.
![A diphtheria skin lesion on the leg. PHIL 1941 lores. A diphtheria skin lesion on the leg. Corynebacterium diphtheriae can not only affect the respiratory system, but the skin as well, where it manifests as an open wound. By CDC [Public domain], via Wikimedia Commons 86194057-28695.jpg](https://imageserver.ebscohost.com/img/embimages/ers/sp/embedded/86194057-28695.jpg?ephost1=dGJyMNHX8kSepq84xNvgOLCmsE2epq5Srqa4SK6WxWXS)
Following an of several days to a week, symptoms often have a sudden onset and typically include a sore throat, malaise, and a mild fever. The disease is further characterized by an exudative, pseudomembrane formation on the mucous surface of the throat, which results from of the organism in the or surrounding areas. The pseudomembrane can become quite thick and may cause respiratory stress through of the breathing passages. Toxin is secreted into the bloodstream, where its presence can result in damage to the heart, nervous system, or other organs. Diagnosis is based upon a combination of symptoms, as well as isolation of the organism in a throat culture.
A less common form of diphtheria may be observed on skin surfaces. It contains that can be spread through contaminated environmental surfaces. Infection generally occurs through small cuts in the skin. Cutaneous diphtheria is characterized by an ulcer that heals slowly. If the organism is a that produces toxin, then damage may result.
Treatment and Therapy
Most diphtheria infections respond to antibiotics, either a single dose of penicillin or a seven-day or ten-day course of erythromycin. Since symptoms are associated with production, the administration of antitoxin is critical to early treatment. Once toxin has been incorporated into the target, cell death is irreversible. Antibiotic treatment, however, does result in the elimination of the organism and the termination of further toxin production.
Vaccination with diphtheria toxoid, an inactivated form of the toxin, has proven effective in immunization against the disease. Prophylaxis is generally started early in childhood as part of the trivalent DPT (diphtheria, pertussis, tetanus) series. Boosters are recommended at ten-year intervals.
Perspective and Prospects
Introduction of the diphtheria in the first decades of the twentieth century served to reduce significantly the incidence of the disease in the West. The use of therapy further reduced the fatality rate associated with this disease, which ranged from 30 to 50 percent at its peak. Diphtheria is almost unknown in the United States in the twenty-first century, with cases rarely reported by state health departments, according to the Centers for Disease Control. The disease still exists in the developing world, with 10,107 cases reported worldwide in 2020, according to the World Health Organization.
Bibliography
“Diphtheria.” Epidemiology and Prevention of Vaccine-Preventable Diseases. Eds. William Atkinson, Charles Wolfe, and Jennifer Hamborsky. 12th ed. Washington, DC: Centers for Disease Control and Prevention, 2011. Print.
Grob, Gerald N. The Deadly Truth: A History of Disease in America. Cambridge: Harvard UP, 2002. Print.
“Immunization, Vaccines, and Biologicals: Diphtheria.” World Health Organization. WHO, 31 July 2015. Web. 29 Apr. 2016.
Martin, Julie J. “Diphtheria.” Health Library. EBSCO Information Services, 19 June 2014. Web. 29 Apr. 2016..
Parker, James N., and Philip M. Parker, eds. The Official Patient’s Sourcebook on Diphtheria. San Diego: Icon Health, 2002. Print.
Shuja, Muhammad Hamza. "Diptheria: A Novel Cause of Concern for Pakiston." Journal of Global Health, 1 Sept. 2023, DOI: 10.7189/jogh.13.03038. Accessed 31 Mar. 2024.
"Surveillance." Centers for Disease Control and Prevention, 9 Sept. 2022, www.cdc.gov/diphtheria/surveillance.html. Accessed 31 Mar. 2024.